Phase 3 Readout

VSTM: Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver

Name: Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver
Start: 2031-02-09
End: 2031-02-09

February 9, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 9, 2031
Company: Verastem, Inc. (VSTM)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver

February 9, 2031

VSTM overview →

Company: Verastem, Inc. (VSTM)
Indication: Low Grade Serous Ovarian Cancer